Elise Jirovec

5PUBLICATIONS
28CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 10, 2026
<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.

Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari

|Apr 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.

Tatiana V Kudling, Dmitrii Bychkov, James H A Clubb

|Feb 05, 2025
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää

|Jan 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.

Santeri A Pakola, James H A Clubb, Tatiana V Kudling

|Mar 28, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Santeri A Pakola, Katriina J Peltola, James H A Clubb

Pageof 1

Frequent Collaborators

5 joint publications

Santeri Pakola

4 joint publications

Akseli Hemminki

4 joint publications

Lyna Haybout

3 joint publications

Tatiana V Kudling